5 Life Lessons I Learned From Cancer

According to the American Cancer Society, the statistics are startling. Cancer is claiming more and more lives every day. The numbers tell us that over 1.6 million people will have been diagnosed by the end of 2014 -- a diagnosis that can rock the foundation of anyone's world. In November 1999, that's what it felt like for me and my husband when he was diagnosed with stage IV cancer -- Non-Hodgkin's Lymphoma. At one point, we asked the oncologist what we could do to help support the hospital treatments and aid in the fight against cancer. "Nothing," he said. I'm sure it's not too hard to imagine how devastating an answer like that was. The diagnosis itself had been enough to knock the wind out of us. We went from being shocked, to afraid, to desperate to take action in repeated loops again and again. It's been a long journey, but cancer has proven to be a patient teacher that will 'gift' you with a wealth of lessons if your mind, heart, and soul are open enough to receive them. Here are the lessons I particularly learned in its classroom: 1) Know When To Fight As aforementioned, my husband's oncologist insisted there was nothing we could do to supplement the chemo treatments. I don't know if this is simply something those in the medical profession are required to say for fear of being held liable for suggesting alternative routes, but I do know that plenty of people take such words at face value and remain discouraged. My husband and I, however, decided we'd t...
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news

Related Links:

The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewIMiDs are a class of biologic agents with immunomodulatory, anti-angiogenic, and direct anti-cancer activities. This review summarizes current data on clinical development and application of IMiDs in non-Hodgkin lymphoma (NHL) subtypes, focusing primarily on lenalidomide, with additional discussion on managing common side effects.Recent FindingsImproved upon the prototype thalidomide, the second-generation compound lenalidomide has enhanced immunological and anti-cancer properties with fewer side effects, while next-generation small molecule cereblon/E3 ubiquitin ligase modulator CC-122 is in early...
Source: Current Hematologic Malignancy Reports - Category: Hematology Source Type: research
CONCLUSIONS: NRP-1 exhibited higher expression in lymphomas, and it was positively expressed in EBV-positive lymphomas. Moreover, highly expressed NRP-1 can be used as an undesirable independent prognostic factor in NHL. PMID: 31282408 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
SAN FRANCISCO - A California man on June 21 sued Monsanto Co. in California federal court, contending that he has developed non-Hodgkin lymphoma (NHL) as a result of exposure to glyphosate, the active ingredient in the herbicide Roundup, which he alleges Monsanto has misrepresented as a safe product (Saul Cohen v. Monsanto Company, No. 19-3632, N.D. Calif.).
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - Category: Medical Law Source Type: news
Authors: Xu J, Wang T Abstract Background: Diabetes mellitus (DM) is considered to be a risk factor in the prognosis of many types of cancer, but the effect of DM on the risk of non-Hodgkin lymphoma (NHL) is still under dispute. We performed this study to examine the association between DM and subsequent NHL risk. Methods: A systematically search had been performed in PubMed, EmBase, and the Cochrane Library to identify eligible studies from inception to September 2018. Results: Thirteen cohort studies were included, with a total of 9024761 participants. The results showed that DM was associated with an increased r...
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Conclusion: Delivery of optimal treatment for DLBCL is associated with hospital location and category, highlighting possible demographic variation in treatment patterns. Together with an increase in the proportion of patients receiving optimal treatment in the more recent time period, this suggests that treatment decisions in DLBCL may be subject to non-clinical influences, which may have implications when evaluating equity of treatment access. The positive association with survival emphasizes the importance of delivering optimal treatment in DLBCL.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
We present a rare case of direct invasion of DLBCL to the stomach wall that presented as upper GI bleeding in a patient with HIV. Diagnosis: Upper endoscopy showed a large ulcerofungating mass in the lesser curvature of upper stomach body. The computed tomography scan showed an about 22 × 12 cm sized huge mass that invades into the stomach wall in the abdominal cavity. A diagnosis of DLBCL was established after histological examination. Intervention: The patient was treated with 6 courses of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Outcomes: The patient achieved a...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Publication date: Available online 26 June 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Amy A. Ayers, Lin Lyu, Kaylin Dance, Kevin C. Ward, Christopher R. Flowers, Jean L. Koff, Lauren E. McCulloughAbstractBackgroundRacial disparities in non-Hodgkin lymphoma (NHL) are not well elucidated for specific catchment areas, which can influence outcomes. Leveraging regional data from a population-based cancer registry may provide unique opportunities to quantify NHL disparities.MethodsUsing Surveillance, Epidemiology and End Results (SEER) data for NHL cases diagnosed in Georgia from 2001 to 2015, we examined NHL i...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
​BY ANGEL BERMUDEZ, MD, &WESLEY EILBERT, MDAn 81-year-old woman with a history of metastatic lung cancer, hypertension, and COPD presented with dizziness that she described as lightheadedness, generalized weakness, and mild shortness of breath for three days. She also reported recent anorexia and a sensation of impending loss of consciousness.She was thin and appeared ill, and she was unable to stand unsupported. She was afebrile with a heart rate of 101 bpm and a blood pressure of 92/55 mm Hg.Her initial ECG is shown. What else could this be if not ST-elevation myocardial infarction?Our patient was found to have a s...
Source: The Case Files - Category: Emergency Medicine Tags: Blog Posts Source Type: research
Abstract Mature B- and T-cell lymphomas are diverse in their biology, etiology, genetics, clinical behavior, and response to specific therapies. Here, we review the principles of diagnostic classification for non-Hodgkin lymphomas, summarize the characteristic features of major entities, and place recent biological and molecular findings in the context of principles that are applicable across the spectrum of mature lymphoid cancers. PMID: 31229154 [PubMed - in process]
Source: The Medical Clinics of North America - Category: General Medicine Authors: Tags: Hematol Oncol Clin North Am Source Type: research
More News: Cancer | Cancer & Oncology | Cardiology | Children | Classrooms | Heart | Hospitals | Internet | Learning | Lessons | Lymphoma | Men | Non-Hodgkin's Lymphoma | Science | Statistics | Tax | Teachers | Teaching | Universities & Medical Training | Websites